Sign inCreate account

Report workspace tools

NCT05107388UNKNOWNanonymous

AAREN: Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer

Sponsor

Source record

Centre Hospitalier Universitaire de Besancon

Phase

Source record

NA

Modality

AI-normalized

medical device

Target

AI-normalized

FreeStyle Libre Pro

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

FreeStyle Libre Pro

Source & freshness

Source record

NCT ID

NCT05107388

Original source

ClinicalTrials.gov

Source last updated

Nov 04, 2021

Ingested at

Jun 07, 2026

Internal sync

Jun 07, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05107388

Title

AAREN: Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer

Sponsor

Centre Hospitalier Universitaire de Besancon

Status

UNKNOWN

Phase

NA

Condition raw

Breast Cancer, Diabetes

Condition normalized

Breast Cancer, Diabetes

Modality raw

medical device

Modality normalized

medical device

Target raw

FreeStyle Libre Pro

Target normalized

FreeStyle Libre Pro

Interventions

FreeStyle Libre Pro

Public preview

Source record

The purpose of this study is to describe the glycemic profile of postmenopausal women treated with alpelisib plus fulvestrant using a continuous blood sugar monitoring device (FreeStyle Libre Pro) over 14 days

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

AAREN: Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05107388

Status

UNKNOWN

Phase

NA

Sponsor

Centre Hospitalier Universitaire de Besancon

Executive brief

Investment-Ready Snapshot

The purpose of this study is to describe the glycemic profile of postmenopausal women treated with alpelisib plus fulvestrant using a continuous blood sugar monitoring device (FreeStyle Libre Pro) over 14 days

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 04, 2021
Internal syncJun 07, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05107388

Indication

Breast Cancer

Modality

medical device

Target

FreeStyle Libre Pro

Intervention

FreeStyle Libre Pro

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.